Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

ASCO 2024 | Update on the PIMMs trial of ivosidenib for patients with IDH1-mutated CCUS

Kelly Bolton • 1 Jun 2024
ASCO 2024
General Ivosidenib
PIMMs

Kelly Bolton, MD, PhD, Washington University School of Medicine, St. Louis, MO, provides a brief update on the PIMMs study (NCT05030441) investigating ivosidenib in patients with IDH1-mutated clonal cytopenia of undetermined significance (CCUS). This interview took place during the 2024 American Society of Clinical Oncology (ASCO) Meeting in Chicago, IL.

These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.

More from Kelly Bolton

Germline predisposition to clonal hematopoiesis and its role in leukemia progression 1:39
Germline predisposition to clonal hematopoiesis and its role in leukemia progression
Kelly Bolton • 1 Jun 2024
CHIP & CCUS: knowledge gaps, ongoing trials & recommendations for hematologists
Eric Padron et al. • 25 Mar 2024
The link between clonal hematopoiesis and COVID-19 9:25
The link between clonal hematopoiesis and COVID-19
Kelly Bolton • 10 Sep 2021

Related Videos

Opportunities and challenges for real-time AI decision support in transplant care 4:47
Opportunities and challenges for real-time AI decision support in transplant care
Amin Turki • 5 Sep 2025
How AI and digital innovation are transforming transplant care 4:02
How AI and digital innovation are transforming transplant care
Amin Turki • 5 Sep 2025
Bringing clinical trials to the community: current approaches at Sarah Cannon Research Institute 1:01
Bringing clinical trials to the community: current approaches at Sarah Cannon Research Institute
Krish Patel • 4 Sep 2025
Stem cell transplant in 2025: latest advances, improving GvHD, and key clinical trials 8:12
Stem cell transplant in 2025: latest advances, improving GvHD, and key clinical trials
Alexandra Gomez-Arteaga • 10 Sep 2025
The content of VJHemOnc is intended for healthcare professionals